The emerging roles of CDK12 in tumorigenesis

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00027162%3A_____%2F17%3AN0000130" target="_blank" >RIV/00027162:_____/17:N0000130 - isvavai.cz</a>

Result on the web

<a href="https://celldiv.biomedcentral.com/articles/10.1186/s13008-017-0033-x" target="_blank" >https://celldiv.biomedcentral.com/articles/10.1186/s13008-017-0033-x</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1186/s13008-017-0033-x" target="_blank" >10.1186/s13008-017-0033-x</a>

Result language

angličtina

Original language name

The emerging roles of CDK12 in tumorigenesis

Original language description

Cyclin-dependent kinases (CDKs) are key regulators of both cell cycle progression and transcription. Since dysregulation of CDKs is a frequently occurring event driving tumorigenesis, CDKs have been tested extensively as targets for cancer therapy. Cyclin-dependent kinase 12 (CDK12) is a transcription-associated kinase which participates in various cellular processes, including DNA damage response, development and cellular differentiation, as well as splicing and pre-mRNA processing. CDK12 mutations and amplification have been recently reported in different types of malignancies, including loss-of-function mutations in high-grade serous ovarian carcinomas, and that has led to assumption that CDK12 is a tumor suppressor. On the contrary, CDK12 overexpression in other tumors suggests the possibility that CDK12 has oncogenic properties, similarly to other transcription-associated kinases. In this review, we discuss current knowledge concerning the role of CDK12 in ovarian and breast tumorigenesis and the potential for chemical inhibitors of CDK12 in future cancer treatment.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

10608 - Biochemistry and molecular biology

Project

<a href="/en/project/NV16-34152A" target="_blank" >NV16-34152A: Targeting ovarian tumors to experimental drugs by inhibition of CDK12 kinase activity</a><br>

Continuities

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2017

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Cell Division

ISSN

1747-1028

e-ISSN

—

Volume of the periodical

—

Issue of the periodical within the volume

12

Country of publishing house

GB - UNITED KINGDOM

Number of pages

10

Pages from-to

7

UT code for WoS article

000414013700001

EID of the result in the Scopus database

—